Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07465302

Treating Spinal Cord Injury With Early Normobaric Hyperoxia

SpiCoH is a phase IIa, single center, open-label, clinical trial of intermittent normobaric hyperoxia in mechanically ventilated patients with traumatic cervical and/or thoracic spinal cord injury.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

University of Florida

Gainesville, Florida, 32610, United States

Location status: Recruiting

Location contact

Andrew Kline

CONTACT

[email protected]

724-496-8034

About this study

Intermittent normobaric hyperoxia (NBH) by increasing FiO2 to 100% for a duration of 4.5h (270 min), twice daily over five consecutive days. Instead of fixed 12-hour intervals between sessions, the two daily treatments will follow a pre-specified interval: a minimum of 1.5h (90min) between sessions for treatment B, and 10h (600min) for treatment A.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Provision of signed and dated ICF by the subject or LAR
  • Stated willingness to comply with all study procedures for the duration of the study
  • Male or female subjects, aged ≥18 and ≤ 85 years
  • Admitted with a diagnosis of blunt or penetrating traumatic cervical and/or thoracic SCI (maintaining dural sac integrity)
  • Awake and able to interact and follow commands
  • American Spinal Injury Association (ASIA) Impairment Scale (AIS) grades A, B or C
  • Need for mechanical ventilation (MV), as determined by the treating physician
  • Baseline PaO2 >80 mmHg before enrollment
  • Capacity to initiate the study intervention within 24 hours of injury

Exclusion criteria

  • Evidence of traumatic brain injury by neuroimaging (either CT or MRI) including, but not limited to, traumatic subarachnoid hemorrhage, subdural hematoma, epidural hematoma, intracranial hemorrhage, parenchymal contusions, and blunt cerebrovascular injury grades II-V
  • AIS grades D or E at time of arrival to hospital
  • Persistent hypoxia requiring >40% FiO2 to maintain PaO2 >80 mmHg
  • Concurrent injuries contraindicating lumbar drain placement, including, but not limited to: signs of infection at insertion site, elevated intracranial pressure, supratentorial mass lesion with mass effect, posterior fossa mass or uncorrected coagulopathy (thrombocytopenia <100,000/μL or International Normalized Ratio >1.5)
  • Pre-existing neurologic conditions that would confound neurologic assessment or would make difficult to accurately assess neurologic and/or functional outcomes
  • Pre-existing respiratory or pulmonary conditions that would impact ventilation mechanics or confound the assessment of respiratory recovery
  • Participation in a concurrent investigational/interventional study (observational studies allowed)
  • Known to be pregnant, or with a positive pregnancy test
  • Vulnerable populations such as prisoners and inmates (abiding GCP per the study IRB)
  • Patient has any other clinically significant medical condition as determined by the investigator, that may unfavorably alter the risk-benefit of study participation, adversely affect study compliance, or confound interpretation of study results

Treatment and study plan

Normobaric Hyperoxia

Other

Intermittent normobaric hyperoxia (NBH) by increasing FiO2 to 100% for a duration of 4.5h (270 min), twice daily over five consecutive days. Instead of fixed 12-hour intervals between sessions, the two daily treatments will follow a pre-specified interval: a minimum of 1.5h (90min) between sessions for treatment B, and 10h (600min) for treatment A.

Primary outcomes

  1. Feasibility of early normobaric hyperoxic therapy

    Time frame: 24 hours from injury

    Proportion of subjects receiving first normobaric hyperoxia therapy.

  2. Preliminary efficacy of intermittent normobaric hyperoxia in achieving high oxygen concentrations systemically

    Time frame: From enrollment to the end of intervention period at 5 days

    Serial PaO2

  3. Preliminary safety of intermittent normobaric hyperoxia

    Time frame: From completion of first treatment to end of 6 month follow up period

    Four-point end-organ toxicity surveillance.

Secondary outcomes

  1. Feasibility of intermittent therapeutic hyperoxemia and elevated oxygen concentration

    Time frame: From enrollment to the end of intervention period at 5 days

    Serial PaO2. Proportion of subjects receiving all 10 planned normobaric hyperoxia treatments.

  2. Exploratory safety objectives

    Time frame: From enrollment to end of 6 month follow up period

    Rates of study termination from demonstrated signs of organ injury attributable to hyperoxia determined by safety monitoring board

  3. Feasibility - Timely Placement of Lumbar Drain

    Time frame: Time of injury to 24hr post injury.

    Proportion of subjects with lumbar drain placed before initiation of normobaric hyperoxia.

  4. Feasibility - Completion of Required Monitoring Lines

    Time frame: Day 0 to day 5

    Proportion of subjects with lumbar drain and arterial line for the duration of 5-day intervention period.

  5. Protocol Adherence - Sampling Deviations

    Time frame: Enrollment to end of 6 month follow up period

    Rate of protocol violations or deviations related to missing samples or samples obtained outside the planned schedule for blood and/or CSF.

  6. Sample Handling - Discarded Specimens

    Time frame: From enrollment to end of 6 month follow up period

    Rate of discarded CSF or blood samples

Study contacts

Contact information is provided by the study sponsor or research team.

Andrew Kline

CONTACT

[email protected]

352-273-9000

Ralisa Pop

CONTACT

[email protected]

(352) 294-5693

Sponsors and collaborators

Lead sponsor

University of Florida

Other

Collaborators

  • National Institute of General Medical Sciences (NIGMS)

Registry information

Official study title

Treating Spinal Cord Injury With Early Normobaric Hyperoxia - A Phase IIa Feasibility Trial

Acronym: SpiCoH

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Mar 11, 2026
Registry last updated
May 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.